Loading patent…
AssigneeCuraGen Corporation
InventorsFerenc L. Boldog, Catherine E. Burgess, Elma R. Fernandes, Michael E. Jeffers, William J. LaRochelle, Henri S. Lichenstein, Jeffrey Peterson, Sudhirdas K. Prayaga, Beth Rittman, Juliette B. Shimkets, Richard A. Shimkets, Meijia Yang
Estimating the term…
The present invention is based upon methods of treating inflammatory conditions in the intestinal tract of mammals using growth factor related polypeptides. The invention includes methods of reducing the mortality rate or delaying mortality in a subject suffering from an inflammatory pathology. Methods of using fibroblast growth factor-CX (FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded by such nucleic acid sequence, or variants, fragments and homologs thereof, are claimed in the invention. Similarly, methods of using FCTRX polynucleotide sequences and the FCTRX polypeptides encoded by such nucleic acid sequences, or variants, fragments and homologs thereof, alone or in combination, are also claimed in the invention. FCTRX collectively refers to any of six variant FCTRX sequences, variously designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.
A method of promoting the growth of a population of cells comprising contacting the at least one cell with a composition comprising at least one polypeptide, wherein the polypeptide is selected from the group consisting of a FGFCX polypeptide, a FCTRX polypeptide, and a combination of a FGFCX polypeptide and a FCTRX polypeptide.
A method of treating an inflammatory pathology in a subject comprising administering to the subject a composition comprising a polypeptide wherein the polypeptide comprises a FGFCX polypeptide or a FCTRX polypeptide or a combination of a FGFCX polypeptide and a FCTRX polypeptide.
A method of delaying the onset of an inflammatory pathology in a subject comprising administering to the subject a composition comprising a polypeptide wherein the polypeptide comprises a FGFCX polypeptide or a FCTRX polypeptide or a combination of a FGFCX polypeptide and a FCTRX polypeptide.
A method of ameliorating an inflammatory pathology in a subject comprising administering to the subject a composition comprising a polypeptide wherein the polypeptide comprises comprises a FGFCX polypeptide or a FCTRX polypeptide or a combination of a FGFCX polypeptide and a FCTRX polypeptide.
A method of preparing a pharmaceutical composition comprising combining at least one polypeptide effective in treating an inflammatory pathology with a pharmaceutically acceptable carrier, wherein the polypeptide is selected from the group consisting of a FGFCX polypeptide, a FCTRX polypeptide, and a combination of a FGFCX polypeptide and a FCTRX polypeptide.
A method of reducing the mortality rate in a subject suffering from an inflammatory pathology comprising administering to the subject a composition comprising a first polypeptide wherein the first polypeptide comprises either a FGFCX polypeptide or a FCTRX polypeptide.
A method of delaying mortality in a subject suffering from an inflammatory pathology comprising administering to the subject a composition comprising a first polypeptide wherein the first polypeptide comprises either a FGFCX polypeptide or a FCTRX polypeptide.
Dependencies are inferred from the claim text.